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! Summary: The technical and diagnostic performance of fully automated immunoassays for free thyroxine and
thyrotropin using streptavidin/biotui technology (Enzymun-Test®) were examined. The between-assay precision for
! free thyroxine was 10.4%, 5.4%, 2.5%, 2.3%, 1.1% and 1.8% at 3.02, 6.27, 17.2, 21.9, 25.6, 42.7 pmol/I; and for
| thyrotropin was 14.2%, 4.7%, 2.9%, 2.8%, 3.2%, 4.5% at 0.12, 0.46, 1.03, 2.05, 4.8, 12.7 mU/1. The functional
1
 detection limit of the assay was 0.09 mU/1. Results for the free thyroxine method correlated well with the IMx
(r =0.91) and the equilibrium dialysis (r = 0.95) assay. Results for the thyrotropin method correlated well with the
Tandem®-TSH (r = 0.99) and the IMx (r = 0.99) assays. The euthyroid reference r nge was 11-23 pmol/1 and
0.5—3.9 mU/1 for free thyroxine and thyrotropin respectively. The free thyroxine assay was not influenced by
changes in albumin or thyroxine binding globulin concentration but showed increases at oleic acid concentrations
| > 4 mmol/1. Spuriously elevated free thyroxine concentration were found in 4 patients, due to assay interference
i by antibodies in the serum. In a follow up study of 46 patients with non-thyroidal illness, serial measurements
* showed fluctuating free thyroxine and thyrotropin concentrations with abnormal results occurring in 34%. In a
hospital setting, a wider r nge pf free thyroxine (10—28 pmol/1) and thyrotropin (0.22—5.9 mU/1) concentration
ι may be observed in patients who are clinically euthyroid. Abnormal thyroid function tests were however transient
, and follow up resolved most diagnostic problems.
Introduction Recently, fully automated tests using streptavidin/biotin
_ . , . . _ , , , , - Λ. ι technology for free thyroxine and thyrotropin (Enzy-The chmcal laborat ry must, tpday, select its free thy- _ TJL . ^ , , ,, ; .
 Λ .
, " . A , . , ~ . mun-Test^) were mtroduced on the automated immuno-
roxine and thyrotropin assays from a multitude of iso- . Τ?ΟΟΛΛ /r> u · \Λ u · \*
, . . , Λ ,ι j assay analyser, ES300 (Boehrmger Mannheim, Mann-
topic and non-isotopic and manual or fully automated , . _ ^
 r * · * *
. . . ' ,, ,f
 rx _, ; f , ^ heim, Germany). In theory, conjugate assays for free
methods available (1^5). The measurement of thyrotro- . . .
 Λ ^ τ *<® ^ +· u
. ~' . t ' ,- · i ; i thyroxine such s the Enzymun^Test® are attractive be-pm and free thyroxine. m serum, iri the clinical labora^ , 1 1 . ^ ^ iK
 / · J . „ , „ . ' , ^ \ . c use they have better accuracy than most analogue
tory is however, still probleimatic. Many free thyroxine , , , ,
 it_ , , , ^
, . . '
 y
 , , „ . .; . methods, and automated methods have better precision
techmques give abnormal v lues for patients with major , . .
 x A, ,
. . ,. . / . , . - . ,. than manual immunoextraction methods.quantitative or qualitative changes in thynoxine binding
to serum proteins, and in non4hyroidal illness, espe- The aim of this study was to evaluate the analytical and
cially in an intensive care unit setting (6). Thyrotropin clinical performance of the Enzymun-Test® FT4 and En-
assays vary in their quoted analytical sensitivity, and in zymun-Test® TSH in a ro tine laborat ry setting.
the use of different calibrators constructed froiii different
non human-based 'Serum matrices (7). Also at present
the majority of commercially available second genera- Materials and Methods
tion thyrotropin assays cannot reliably distinguish be- samples
tween mildly subnormal thyrotropin v lues seen i n hos- - u r - i ^ u - j A . f i ,
. ,. - . „ , /. , . t - T° determme the reference mtervals for thyrotropin and free thy-
pitahsed patients and the low v lues found m thyrotoxic
 roxinej the serum concentrations were raeasured in IOO healthy
patients (8). euthyroid individuals (age 45 ± II years% 58 male, 42 female).
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Similarly free thyroxine and thyrotropin in the first and third tri-
mester of pregnancy, oestrogen containing oral contraceptive and
Hormone replacement therapy wcre determined in apparently heal-
thy cuthyroid subjects.
For method comparison studies, patient sera sent for routine thyroid
function tests were used, and included hypo, hyper and euthyroid
patients s well s those on thyroxine and the antiarrhythmic
drug amiodarone.
The serum free thyroxine and thyrotropin were followed in two
groups of patients with non-thyroidal illness. Group (1), 40 patients
(age 74 ± 9 years, 30 male, 10 female) admitted to a general medi-
cal ward, with a variety of illness ranging from hairy cell leukae-
mia, cholecystitis, carcinoma of prostate, vertebral fractures, con-
gestive cardiac failure, were followed over a period of l to 3
months. Following a retrospective study of the patients' medical
records 5 patients with previous history of thyroid disease, 3 pa-
tients on steroid therapy and 4 patients on amiodarone were ex^
cluded from the study.
Group (2), 21 patients (age 74 ± 5 years, 20 male, l female) admit-
ted consecutively to an intensive care unit were followed over a
period of l to 5 weeks. The clinical conditions of the patients var-
ied from bypass graft surgery, severe dehydration, partial gastrec-
tomy, thrombectomy and aneurysm repair. Following patient re-
view, 2 patients with prior record of thyroid disease and l patient
on amiodarone were excluded from the study.
Method
Thyrotropin
The Enzymun-Test® thyrotropin assay is a two site immunoenzy-
mometric assay involving a biotin labelled antibody and a second
monoclonal antibody directed against a different antigenic site, la-
belled with horseradish peroxidase. Separation was by means of
streptavidin coated tubes. The assay was performed according to
manufacturer's specification, on the ES300. Seventy μΐ of serum
were incubated for 60 minutes at 25 °C, with 700 μΐ of thyrotropin
biotinylated antibodies (1.5 mg/1) and antibody conjugate in 80
mmol/1 phosphate buffer pH 7.4. The streptavidin coated tubes
were aspirated and washed and the Substrate diammonium 2,2-
azino-bis(3-ethylbenzothiazine-6-sulphonate) added. The colour in-
tensity developed in thirty minutes was read at 422 nm.
The Standard concentrations, made up in 'protein matrix', approxi-
mated to 0.03, 0.3, 1.02, 9.55, 40.2 mU/l.
Free thyroxine
The Enzymun-Test® FT4 assay was carried out according to kit
inserts, on the ES300. Twenty μΐ of sample or serum was incubated
for 30 minutes at 25 °C, with 500 μΐ of biotinylated polyclonal
sheep anti-T4 antibodies (antibody content ^ 100 μ^/l) in 50
mmol/1 barbiturate buffer pH 8.2. Thyroxine peroxidase conjugate
(500 μΐ) was then added. After a further incubation for 30 minutes
the streptavidin tubes with the reaction mixture were aspirated,
washed and the Substrate added. All patient sera were measured in
singleton, for both assays.
Sensitivity
Analytical sensitivity, i. e. the minimum concentration at which re·-
sults from a serum specimen can be considered statistically dif-
ferent from a zero calibrator + 2.7 SD (99% confidence limit), the
latter assayed 10 times, in singleton.
Precision studies
The between assay precision was calculated from the means of 10
singleton measurements of serum specimen aliquoted and stored at
—20 °C, and frorn three quality control sera with Iow, medium and
high values. The assays were carried out over a period of days
(thyrotropin) or weeks (free thyroxine).
The within assay precision was ca'lculated from 10 singleton se-
rum specimens.
Linearity ' r
Linearity for thyrotropin was evaluated by two difFerent parallelism
studies. Serial dilutions were made of a sample with a high level
of thyrotropin with serum containing undetectable levels of thyro-
tropin, or the thyrotropin diluent provided with the kit. A second
sera with a value within the reference r nge was diluted with thyro-
tropin diluent to test linearity over the lower r nge of the assay.
Method comparison
The accuracy of the free thyroxine method was investigated by
comparison with an equilibrium dialysis method (RIA analysis of
the dialysate of the undiluted serum, Nichols Institute, San Juan
Capistrano, Ca) and by the automated Abbott IMx System (Abbott
Park, II., thyroxine specific antibody on microparticles with micro-
particle enzyme immunoassay technology). The thyrotropin
method was compared to the Abbott IMx System (Immunoenzymo-
metric assay with micrpparticle technology, manufacturer's detec-
tion limit 0.03 mU/l, referenee r nge 0.32-5.0 mU/l) and the Tarn
dem®-TSH (Hybritech, San Diego, Ca) high sensitivity assay (Au-
tomated immunoenzymometric assay using coated beads, manufac-
turer's detection limit 0.1 rnU/I, reference r nge 0.5—6.7 mU/l).
Other assays
Serum thyroxine binding globulin and free triiodothyronme were
measured by the Enzymun-Test® assays on the ES300. Prealbumin
and human serum albumin were measured by rate nepheiometry
on the Beckman Array (Beckman Instruments, Ca.).
Assay interference
a. Non-esterifled fatty acids - oleic acid in concentrations from
1 — 10 mmol/1 was added to * normal' serum from an apparently
healthy indiividual and to patient sera with Iow and normal albumin
levels (usirig the method of Mendel et al. (9)), i. e. an aliquot of a
solution in isopropanol was evaporated under helium and the resi-
due taken up at 37 °C in serum solution.
b. Albumin — various concentrations of human serum alburnin, fatty
acid free (Sigma Chemical Company, St Louis) were added to patient
sera with Iow albumin concentration. Negligible levels of free thy-
roxine were detected in Solutions of human serum lbumi (40 g/l,
20 g/l) when measured by equilibrium dialysis and Enzymun-Test®
FT4, suggesting that the albumin solution was essentially stripped of
thyroxine. Patient sarnples were spiked such that minimal change in
volume occurred (i. e. 180 μΐ of concentrated albumin solution to
2 ml) and the albumin level in the patient sera rneasured by nepbe^
lometry. These samples were then assayed for free thyroxine by the
Enzymun-Test® or equilibrium dialysis assay.
c. To determine the nature of proteins causing assay interference
- Agarose linked goat anti-human polyvalent immunoglobulins or
agarose linked goat anti-human IgG (Sigma Chemical Company),
was mixed and centrifuged to remove excess liquid. Two hundred
μΐ of serum were incubated with 200 ^g of the solid phase anti-
body. Free thyroxine assays were carried out on the preincubated
serurn.
S tat i s ti es
The curvefit method for the Enzymun-Test® FT4 and Enzym m
Test® TSH was a Rodbard proced re. Recalibrati n was a single
point calibration on the third highe^t Standard (thyrotrojpin) or the
Eur. J. Cliix.-Chem. Clin. Biochem. / Vol. 32, 4994 / No. 7
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second highest Standard (free thyroxine). Linear regression analysis
was used to test correlation between the different methods.
Results
Sensi t ivi ty
The analytical sensitivity was 0.08 mU/1 for thyrotropin
and 1.2 pmol/1 for free thyroxine. For thyrotropin the
functional sensitivity (between-assay CV 10%) approxi-
mated to 0.19 mU/1, or (between-assay CV 20%) 0.09
mU/1. The analytical and functional sensitivity of the
thyrotropin assay was similar to second generation thy-
rotropin assays previously studied (10).
Tab. 1 Methods used for comparison - Inter-assay precision
data*.
Method
Tandem®-TSH (mU/1)
mean
CV%
Thyrotropin, IMx (mU/1)
mean
CV%
Free thyroxine, IMx (pmol/1)
mean
CV%
Free thyroxine, equilibrium dialysis
(pmol/1)
mean
CV%
0.6
9.6
0.27
4.6
8.6
7.4
9.7
3.4
6.3
3.8
15.1
4.1
19.4
10.9
38.7
3.6
53.4
6.6
36.0
4.2
30.9
14.0
Precision
Within- and between-assay precision are shown in figure
l la,b. The precision profile for thyrotropin showed the
inverse relationship with low thyrotropin previously re-
jported for other assays (10). The between-assay
j precision values for both assays, over the euthyroid
i ränge, feil within the calculated analytical goals based
on intra-individual components of biological Variation
(11). Table l shows the inter-assay precision (CV) for
the methods used for comparison.
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Fig. l Imprecision profile for (a) free thyroxine, Enzymun-Test®
FT4, (b) thyrotropin, Enzymun-Test® TSH
ü within run precision
o between run precision
Insert shows the Standard curve.
n = 10
Linearity
Dilution experiments with thyrotropin diluent or a se-
cond serum showed linear dilution curves over the ränge
3.5-54 mU/1 and 0.1-3.4 mU/1.
Comparison of methods
L Analytical performance
Figure 2a,b compares the Enzymun-Test® FT4 assay
with IMx free thyroxine, and free thyroxine (FT4) by
equilibrium dialysis. The assays correlated well with the
following regression equations: FT4 (ES300) = 3.0
+ 0.95 FT4 (IMx) (r = 0.91, n = 98, Sy/x = 4.0) and
FT4 (ES300) = 3.52 + 0.68 FT4 (Equilibrium dialysis),
(r = 0.95, n = 61, Sy/x = 3.2).
Figure 3a,b compares the Enzymun-Test® TSH assay
with thyrotropin by IMx and IMx and thyrotropin (TSH)
by the Tandem®-TSH assay. The assays correlated well
with the following regression equations: TSH (ES300)
= 0.008 + 1.17 TSH (IMx) (r = 0.99, n = 41, Sy/x
= 0.39) and TSH (ES300) = 0.29 -l· 1.00 TSH (Hybri-
tech) (r = 0.99, n = 97, Sy/x = 0.5).
2. Diagnostic performance
Serum free thyroxine äs measured by the Enzymun-
Test® and equilibrium dialysis methods concurred in the
clässification of 48 patients with free thyroxine values
in the euthyroid ränge, 11 patients with free thyroxine
in the hyperthyroid ränge and 2 patients with free thy-
roxine in the hypothyroid ränge. Free thyroxine by the
ES300 and free thyroxine (IMx) agreed in the assess-
ment 58 patients with free thyroxine in the euthyroid
ränge, 27 patients with elevated free thyroxine concen-
tration, and 10 patients with free thyroxine values below
Eur. J. Clin. Chem. CKn. Biochera. / Vol. 32,19941 No. 7
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Fig. 2 Linear regression analysis between Enzymun-Test® FT4 Fig. 3 Linear regression analysis between Enzymun-Test® TSH
and free thyroxine by (a) equilibrium dialysis (ED), (b) IMx. and thyrotropin by (a) IMx, (b) Hybritech Tandem® - TSH.
the reference ränge. However, 3 patients with free thy-
roxine values of 28.0, 33.0, 29.0 pmol/l by the Enzy-
mun-Test® were classified äs euthyroid by the IMx
method. There were no clear reasons for these discor-
dant values.
Serum thyrotropin äs measured by the Enzymun-Test®
and Hybritech correctly classified 69 patient sera with
thyrotropin values within the reference ränge, 21 patient
sera with thyrotropin above 'the reference ränge and 3
patients with suppressed thyrotropin. Four patients with
thyrotropin levels within the reference ränge by the Hy-
britech method were classified äs hypothyroid by the
Enzymun-Test® method with thyrotropin values in the
ränge 3.9-4.5 mU/l. Similarly thyrotropin by the Enzy-
mun-Test® agreed with thyrotropin by IMx in the assess-
ment of 28 patients with thyrotropin in the euthyroid
ränge, 10 patients with elevated thyrotropin, and 3 pa-
tients with suppressed thyrotropin.
A further 17 patients (not included in the regression
analysis) were classified äs having undetectable thyro-
tropin by the IMx and Enzymun-Test® methods, but 9
patients with undetectable values by the IMx method had
low but detectable values (0.1-0.16 mU/l) by the Enzy-
mun-Test® method. Three patients with thyrotropin Val-
ues below the detection limit by the Tandem®*TSH as-
say had undetectable values by the Enzymun-Test® as-
say.
As the percentage of rnisclassifications were small
(< 4.0%), the diagnostic performance of Enzymun-
Test® methods were considered to be equivalent to the
comparison techniques; the characteristics of the latter
have been described in previous studies (12-15).
Reference rariges
v'
The noii-parämetric reference intervals (0.025 and 0.975
fractiles) were 11-23 pmol/l for FT4 and 0.5-3.9 mU/l
for thyrotropin (tab. 2). The free thyroxine mean valüe
in the first trirnester of pregnancy, 14.8 pmol/l, was
found to be significantly higher (p < 0.01) than the
Eur. J-. Clin: Chem. Clin. Biochem. / Vol. 32,1994 / No. 7
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Tab. 2 Ranges of free thyroxine, thyrotropin and thyroxine binding proteins for an euthyroid population.
Euthyroid
Ist trimester pregnancy
3rd trimester pregnancy
Hormonal contraception
Hornone replacement therapy
n
100
20
20
20
20
Free
thyroxine
(pmol/1)
11-23
10-19
9-14
12-20
12-20
Thyrotropin
(mU/1)
0.5-3.9
0.4-3.2
0.5-2.4
0.6-3.4
0.7-3.3
Thyroxine
binding
globulin
(mg/1)
8-22*
14-31
17-36
15-28
14-29
Prealbumin
(mg/1)
150-290
180-300
240-450
200-420
Albumin
(g/l)
34-44
26-39
33-45
33-44
n = 33
_; mean value in the third trimester, 11.6 pmol/1. The Enzy-
[J mun-Test® FT4 yielded normal results in Hormone re-
i placement and contraceptive pill therapy, despite in-
creases in thyroxine binding globulin, suggesting that
the conjugate does not bind to thyroxine binding globu-
lin. Thyrotropin values for the latter groups feil within
:
 the reference ranges.
Assay interference
a. Oleic acid
Addition of oleic acid at values greater than 4 mmol/1
i increased the estimates of free thyroxine by both equi-
1
 librium dialysis and the Enzymun-Test® method in a se-
rum sample from a 'normal' individual with an albumin
value of 41 g/l and prealbumin of 250 mg/1. The increase
in free thyroxine suggests that thyroxine is displaced
from albumin and at higher concentrations from albumin
and thyroxine binding globulin by non-esterified fatty
acids (33). Patient sera with low values of albumin re-
sponded more sensitively than patient sera with albumin
within the reference ränge (fig. 4). Endogenous free
0 2 4 6 8
Oleic acid [mmol/l]
Fig. 4 Effect of oleic acid on free thyroxine measurements:
B Free thyroxine by Enzymun-Test® 'normal sera', albumin 41 g/l,
prealbumin 250 mg/1;
G Free thyroxine by equilibrium1 dialysis 'normal sera', aäbumin
41
 g/l, prealbumin 25p .mg/1.
Free thyroxine by 'Enzymun^Test® in patient sera with albumin
41
 g/l, prealbumin 288 mg/1, thyroxine binding globulin 11.9 mg/1.
• Free thyroxine by Enzymun-Test®, in patient sera with albumin
21
 g/l, prealbumin 80 mg/l, thyroxine binding globulin 15.6 mg/1.
fatty acids were not measured in patient sera but were
assumed to be negligible in normal sera.
b. Albumin
Enzymun-Test® FT4 values ranged from 16.4 ± 0.21
pmol/1 at 21 g/l albumin, 16.2 ±0.15 pmol/1 at 27 g/l
albumin, 16.0 ± 0.22 pmol/1 at 31 g/l albumin, 16.2 ±
0.24 pmol/1 at 36 g/l albumin and 15.9 ± 0.15 pmol/1 at
41 g/l of albumin when a patient's sera was spiked with
increasing concentrations of human serum albumin. For
the same sera equilibrium dialysis free thyroxine values
ranged from 26.3 ± 1.37 pmol/1,24.8 ± 2.0 pmol/1,21.8
± 2.9 pmol/1, 21.8 ± 2.7 pmol/1 and 20.2 ± 1.3 pmol/1.
An average of 6 determinations is given at each concen-
tration,
The negligible effect of added albumin suggests that the
horseradish peroxidase labelled thyroxine does not sig-
nificantly bind to albumin. The slight decrease in free
thyroxine values by equilibrium dialysis is explained by
the long dialysis time (ovemight) resulting in increased
binding of thyroxine to serum albumin. As suggested
from the regression line the results from the equilibrium
dialysis method were generally higher than the Enzy-
muri-Test® FT4. These variations are reflected in the dif-
ferent reference ranges for both assays (Table 3).
c. Antibody
Four subjects, patients A—D, whose serum free thyrox-
ine values by equilibrium dialysis and IMx were within
the reference ränge, gave values above the reference
ränge by the Enzymun-Test® FT4 method (tab. 3). Thy-
rotropin, free triiodothyronine, thyroxine binding globu-
lin, and prealbumin values were within the reference
ränge. Preincubation of the patients' sera with agarose
linked goat anti-human immunoglobulin, or agarose
liiiked goat anti-human IgG decreased free thyroxine
values by 52-71% compared to 7-20% in controls,
suggesting that the cause of the spuriously elevated free
thyroxine levels, were antibodies (type IgG) present in
the sera.
Eur. J. Ciin. Chem. Gin. Biochem. / Vol. 32,1994 / No. 7
554 Mattiazzo and Ramasamy: EIA's for free thyroxine and thyrotropin
Tab. 3 Thyroid funclion tests: Immunoglobulin interference in the assay.
Patient
A
B
c
D
Controls
(n = 20)
Reference
ranges
Free thyroxine
Enzyrnun-Test®
(pmol/1)
47.3
39.5
30.0
29.6
11-23
Equilibrium
dialysis
(pmol/1)
27
23
15
18
10-36
IMx
(pmol/1)
20
19.4
12.9
17.4
9-24
Free
triiodothyronine
(pmol/1)
6.1
4.9
7.0
5.7
4.6-9.2
Thyrotropin
(rnU/1)
1.1
2.8
0.46
3.7
0.5-3.9
Recovery*
(%)
29
41
48
41
86.7 ± 2.3
* Free thyroxine recovery after incubation of patient samples, and controls with agarose iinJked goat
anti-human immunoglobulins.
Clinical evaluation
Group 1: Of the selected patients, 3 patients died during
the study Of these, a single patient with chronic renal
failure had an abnormal thyrotropin concentration (5.6
mU/1). As in these patients, the focus of treatment was
towards the underlying non-thyroidal illness, the abnor-
malities associated with thyroid function tests caused
minimal interpretative problems.
In 8 of the remaining 25 patients, thyroid function tests
showed transient abnormalities (tab. 4). One patient had
consistently abnormal thyroid function tests over a fol-
low up period of one month (free thyroxine 28.2 pmol/1,
thyrotropin 4.9 mU/1). In this patient thyroid function
tests became abnormal during repeated admissions for
pulmonary oedema and furosemide therapy. As pre-
viously, her results were within the reference ränge (free
thyroxine 15.1 pmol/1, thyrotropin 2.8 mU/1), her abnor-
mal results were attributed to drug therapy. Overall in
Tab. 4 Transient abnormal thyroid function test results in patients
with non-thyroidal illness.
Patient
Group 1
1
2
3
4
5
6
7
8
Group 2
1
2
3
Free thyroxine
(pmol/1)
26.3
25.7
27.0
27.0
20.9
16.4
20.8
19.1
17.5
19.7
15.8
Thyrotropin
(mU/1)
1.0
3.7
1.9
1.0
4.2
4.4
4.7
5.9
4.7
5.9
0.24
hospitalised patients, classified äs euthyroid, the free
thyroxine values ranged frorn 11 to 28 pmol/1 and thyro-
tropin values from 0.5 to 5.9 mU/1.
Group 2: In the subgroup of selected patients, 5 patients
died subsequently, and of these 3 patients had abnormal
thyroid function tests at least one during follow üp (free
thyroxine 11.3 pmöl/1, thyrotropin 0.22 mU/1; free thy-
roxine 9.7 pmol/1, thyrotropin 0.72 mU/1; free thyroxine
21.3 pmol/1, thyrotropin 4.4 mU/1). A further 3 patients
had transiently abnormal results (tab. 4). Two patients
had consistently high but fluctuating thyrotropin levels
(12.6 to 6.6 mU/1 and 4.5 to 7.9 mU/1) over a period of
4 weeks, suggestive of subclinical hypothyroidism.
In the remaining 8 patients a shift of free thyroxine val-
ues to higher concentrations was observed äs the patient
recovered. Free thyroxine and thyrotropin values feil
within the reference ranges thoügh there was consider-
able intraindividual Variation during follow up (fig.
5a,b). In patients in the intensive care unit, classified äs
euthyroid, free thyroxine ranged from 10—23 pmol/1 and
thyrotropin from 0.22 to 5.9 mU/1.
Discussion
Several aspects of the thyrotropin and free thyroxine äs-
says routinely in use in the laboratory were investigated
during this evaluation. Precision, linearity and rnethod
comparison for the Enzymun-Test® TSH and Enzymuri-
Test® FT4 were acceptable for clinical use. The ftmc-
tional assay sensitivity of 0.09 mU/1 suggested that this
was a second generation assay. Both assays were practi-
cable and easy to use.
Long term low dose heparin therapy used in an intensive
cäre setting can cause increases in plasma free fatty acid
concentrations. Additions oft pleic äcid, the rhost abun-
Eur. j. Clin. Chem. Clin. Biochem. / Vol. 32, 1994 / No. 7
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 Fig. 5 Intraindividual Variation after admission to the intensive
j care unit (a) free thyroxine (b) thyrotropin.
dant non-esterified fatty acid present in the serum (17),
caused an increase in free thyroxine concentrations
when levels reached approximately > 4 mmol/1. Free
thyroxine by equilibrium dialysis responded similarly.
However, the clinical relevance of this observation is yet
to be determined äs the molar ratio of free fatty acids/
albumin that have a discernible effect on free thyroxine
concentration is thought to vary from 2.5 (19, 20) to
> 5.0 (16, 18).
Because dependence on carrier proteins might reduce
the clinical usefulness of free thyroxine methods (21),
we assessed the effect of albumin on the Enzyme-Test®
FT4 assay.
Our results suggest that the current assay, like the equi^·
librium dialysis method is relatively free of albumin or
thyroxine binding globulin dependence. This agrees with
the manufacturer's claim that the horseradish peroxidase
label is prevented from occupying serum triyroxine bind-
ing sites by steric hindrance.
Free thyroxine concentrations rrieasured by the Enzy-
mun-Test® assay decreases during the course of preg-
nancy, although individual results are only slightly be-
low the reference ränge. As the technique yields results
within the reference ränge in subjects with increases in
thyroxine binding globulin äs in hormone replacement
or oestrogen therapy, at least part of the decrease can be
assumed to be physiological (22); such individuals re-
main euthyroid with thyrotropin levels within the refer-
ence ränge.
The study suggests that there is no perfect free thyroxine
assay, äs the theoretical premise of non-interference by
antibodies in the assay is not fulfilled. This has been
previously reported for other non-analogue assays (23,
24). The nature of the antibody, however, is yet to be
determined. Anti-sheep antibodies affecting a radio-
immunoassay for thyrotropin has been reported (25).
These heterophilic antibodies can prevent the binding of
the biotin labelled thyroxine antibodies to the streptavi-
din coated tubes, leading to spuriously high values. An
isolated increase in free thyroxine should therefore be
viewed with caution.
Non-thyroidal illness has been shown to affect thyroid
function tests (26—32). Thyroid function tests are there-
fore optimally performed in ambulatory and otherwise
well patients, but there is a clinical need for determining
the presence or absence of thyroid disease in patients
with non-thyroidal illness. This is especially true in el-
derly patients > 50 years, who suffer from chronic ill-
nesses and benefit from treatment for thyroid dysftmc-
tion äs well äs in patients with myocardial infarction
where the presence or absence of thyroid disease is to
be established. The study shows that in such patients,
normal, low or borderline high thyrotropin/free thyrox-
ine values are possible. In most patients abnormalities in
thyroid function tests were, however, transient. Further-
more, we noted that nqne of the patients had a subnor-
mal thyrotropin and increased free thyroxine (suggestive
of hyperthyroidism) or a high concentration of thyrotro-
pin with a low free thyroxine (suggestive of hypothy-
roidism). Abnormal thyroid function tests associated
with nori-thyroidal illness, therefore caused few inter-
pretative problems. Persistent increased or decreased
thyrotropin concentrations during follow up may indi-
cate subclinical hyper/hypothyroidism.
The average age in both groups of patients with non-
thyroidal illness was 74 years. Although it has been re-
ported that aging influences the outcome from thyroid
function testing (12), there is evidence that 'normal'
aging has little effect, i. e. when pharmacological and
methodological effects are removed (34). The low pre-
valence of subnormal thyrotropin concentrations and the
transient nature of the abnormalities, confirmed in previ-
ous studies with younger patients (27), suggest that the
changes observed during non-thyroidal iilness are not an
age-felated effect.
Doctor et al. (35) showed that in a large proportion of
patients with non-thyroidal illness other non-analogue
free thyroxine assays showed values above the reference
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ränge. Coupled with the observation of anomalous thy-
rotropin values in non-thyroidal illness, a strategy re-
commended in a hospital setting is the use of thyrotropin
and free thyroxine assays on all patients with noii-thy-
roidal illness (36, 37). The present study suggests that
with the Enzymun-Test® technology diagnostic prob-
lems will arise infrequently with this approach. Further,
automation of free thyroxine and thyrotropin will facili-
tate their concurrent measurement with minimal increase
in manpower and laboratory time.
In summary, we found the Enzymun-Test® assays to be
precise, of adequate sensitivity and robust, However, in
a hospital setting, non-thyroidal illness and in vitro assay
interference may compromise the clinical sensitivity and
specificity of thyrotropin and free thyroxine measure-
ment, such that measurement r of both analytes is re-
quired for initial evaluation of thyroid function. Auto-
mated immunoassay analysers, such äs the ES300, make
this approach econoinically more feasible.
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